NIV-话题@MedSci

#NIV#

134篇内容 | 1396人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2007911, encodeId=2119200e9118e, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=NEJM：Nivolumab + ipilimumab一线治疗非小细胞肺癌, objectType=article, longId=183382, objectId=556b183382e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=556b183382e6, replyNumber=0, likeNumber=38, createdTime=2019-11-24, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=556b183382e6, moduleTitle=NEJM：Nivolumab + ipilimumab一线治疗非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=556b183382e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007906, encodeId=05d1200e906b2, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=2019 ASCO：Nektar Therapeutics公布其IL-2激动剂Bempeg与Nivolumab联用的临床数据, objectType=article, longId=167543, objectId=1bb016e5435e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1bb016e5435e, replyNumber=0, likeNumber=39, createdTime=2020-03-12, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1bb016e5435e, moduleTitle=2019 ASCO：Nektar Therapeutics公布其IL-2激动剂Bempeg与Nivolumab联用的临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1bb016e5435e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007907, encodeId=cc65200e907a3, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=Lancet Haematology：Nivolumab联合一线化疗治疗急性髓系白血病, objectType=article, longId=177285, objectId=c6391e7285a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c6391e7285a6, replyNumber=0, likeNumber=37, createdTime=2019-09-14, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c6391e7285a6, moduleTitle=Lancet Haematology：Nivolumab联合一线化疗治疗急性髓系白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c6391e7285a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007908, encodeId=5aa6200e908b8, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=Lancet Oncol：Nivolumab治疗与晚期非小细胞肺癌患者4年生存期, objectType=article, longId=177733, objectId=5c4f1e77336b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5c4f1e77336b, replyNumber=0, likeNumber=25, createdTime=2020-04-22, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5c4f1e77336b, moduleTitle=Lancet Oncol：Nivolumab治疗与晚期非小细胞肺癌患者4年生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5c4f1e77336b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007909, encodeId=5336200e90902, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=WCLC 2019：评估脂质体伊立替康（ONIVYDE）作为小细胞肺癌的二线疗法, objectType=article, longId=179176, objectId=99521e9176c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=99521e9176c4, replyNumber=0, likeNumber=37, createdTime=2020-04-23, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=99521e9176c4, moduleTitle=WCLC 2019：评估脂质体伊立替康（ONIVYDE）作为小细胞肺癌的二线疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=99521e9176c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007905, encodeId=d470200e90555, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=晚期非小细胞肺癌一线治疗新方法：TG4010+Nivolumab+化疗方案的II期试验, objectType=article, longId=167059, objectId=934c16e059fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=934c16e059fc, replyNumber=0, likeNumber=26, createdTime=2020-03-07, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=934c16e059fc, moduleTitle=晚期非小细胞肺癌一线治疗新方法：TG4010+Nivolumab+化疗方案的II期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=934c16e059fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007901, encodeId=93e4200e90170, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=Opdivo（nivolumab）联合Yervoy（ipilimumab）具有转移性去势抵抗性前列腺癌患者的治疗希望, objectType=article, longId=160343, objectId=61541603433f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=61541603433f, replyNumber=0, likeNumber=24, createdTime=2019-08-02, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=61541603433f, moduleTitle=Opdivo（nivolumab）联合Yervoy（ipilimumab）具有转移性去势抵抗性前列腺癌患者的治疗希望, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=61541603433f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007899, encodeId=e45e200e8996a, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=Lancet oncol：Nivolumab联合伊匹单抗或单独用于治疗晚期黑色素瘤可获得持久稳定的疗效, objectType=article, longId=152046, objectId=95d615204647, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=95d615204647, replyNumber=0, likeNumber=34, createdTime=2019-07-17, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=95d615204647, moduleTitle=Lancet oncol：Nivolumab联合伊匹单抗或单独用于治疗晚期黑色素瘤可获得持久稳定的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=95d615204647)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007900, encodeId=619a200e90085, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=【2018 ESMO】立足实践，Nivolumab真实世界研究与临床试验结果遥相呼应, objectType=article, longId=152203, objectId=9b9e15220396, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9b9e15220396, replyNumber=0, likeNumber=33, createdTime=2019-02-20, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9b9e15220396, moduleTitle=【2018 ESMO】立足实践，Nivolumab真实世界研究与临床试验结果遥相呼应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9b9e15220396)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007898, encodeId=0a1d200e898cb, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=澳大利亚TGA批准OPDIVO（nivolumab）治疗肝癌, objectType=article, longId=149518, objectId=81ba14951861, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=81ba14951861, replyNumber=0, likeNumber=21, createdTime=2019-09-05, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=81ba14951861, moduleTitle=澳大利亚TGA批准OPDIVO（nivolumab）治疗肝癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=81ba14951861)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007902, encodeId=287e200e90233, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=J Endod：Micro-CT观察XP-endo Shaper, Reciproc Blue和ProTaper Universal NiTi对牙本质隐裂形成的, objectType=article, longId=163267, objectId=5cca16326e31, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5cca16326e31, replyNumber=0, likeNumber=38, createdTime=2019-04-02, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5cca16326e31, moduleTitle=J Endod：Micro-CT观察XP-endo Shaper, Reciproc Blue和ProTaper Universal NiTi对牙本质隐裂形成的, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5cca16326e31)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007893, encodeId=0aad200e89343, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=Lancet：推荐将nivolumab联合伊匹单抗作为无症状未治疗过的黑色素瘤脑转移患者的一线疗法, objectType=article, longId=133714, objectId=5089133e14b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5089133e14b6, replyNumber=0, likeNumber=44, createdTime=2018-12-09, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5089133e14b6, moduleTitle=Lancet：推荐将nivolumab联合伊匹单抗作为无症状未治疗过的黑色素瘤脑转移患者的一线疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5089133e14b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007891, encodeId=7147200e891d6, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=JCO：Nivolumab治疗晚期非小细胞肺癌的5 年随访结果, objectType=article, longId=133426, objectId=9bfb133426b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9bfb133426b8, replyNumber=0, likeNumber=36, createdTime=2018-12-02, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9bfb133426b8, moduleTitle=JCO：Nivolumab治疗晚期非小细胞肺癌的5 年随访结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9bfb133426b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007896, encodeId=920e200e896dc, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=辉瑞生物仿制药Nivestym获FDA批准用于治疗中性粒细胞减少症, objectType=article, longId=145075, objectId=ca0b1450e5d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ca0b1450e5d7, replyNumber=0, likeNumber=28, createdTime=2019-02-27, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ca0b1450e5d7, moduleTitle=辉瑞生物仿制药Nivestym获FDA批准用于治疗中性粒细胞减少症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ca0b1450e5d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007897, encodeId=cbd5200e897e1, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=JCO：Nivolumab和Nivolumab联合Ipilimumab治疗转移性食管胃癌患者, objectType=article, longId=147192, objectId=187c14e1923f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=187c14e1923f, replyNumber=0, likeNumber=35, createdTime=2019-03-05, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=187c14e1923f, moduleTitle=JCO：Nivolumab和Nivolumab联合Ipilimumab治疗转移性食管胃癌患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=187c14e1923f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007883, encodeId=bc07200e88333, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=Lancet Oncol：Nivolumab单抗或是化疗耐药后晚期食管鳞癌的新选择, objectType=article, longId=122114, objectId=14b712211476, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=14b712211476, replyNumber=0, likeNumber=27, createdTime=2018-08-27, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=14b712211476, moduleTitle=Lancet Oncol：Nivolumab单抗或是化疗耐药后晚期食管鳞癌的新选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=14b712211476)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007885, encodeId=8cf9200e885cd, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=治疗黑色素瘤 Opdivo®(Nivolumab)疗效优于Yervoy®(Ipilimumab), objectType=article, longId=122648, objectId=9aba12264896, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9aba12264896, replyNumber=0, likeNumber=31, createdTime=2018-10-11, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9aba12264896, moduleTitle=治疗黑色素瘤 Opdivo®(Nivolumab)疗效优于Yervoy®(Ipilimumab), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9aba12264896)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007889, encodeId=1472200e88956, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=EUR J Cancer：Pembrolizumab治疗晚期黑色素瘤后使用伊匹单抗/nivolumab治疗的风险较低, objectType=article, longId=125181, objectId=e829125181d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e829125181d4, replyNumber=0, likeNumber=27, createdTime=2018-01-15, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e829125181d4, moduleTitle=EUR J Cancer：Pembrolizumab治疗晚期黑色素瘤后使用伊匹单抗/nivolumab治疗的风险较低, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e829125181d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007882, encodeId=3519200e88201, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=AASLD特约点评 | 赵明教授：Checkmate-040 研究——Nivolumab治疗晚期HCC的数据更新, objectType=article, longId=121557, objectId=f7f212155e0e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f7f212155e0e, replyNumber=0, likeNumber=33, createdTime=2018-07-14, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f7f212155e0e, moduleTitle=AASLD特约点评 | 赵明教授：Checkmate-040 研究——Nivolumab治疗晚期HCC的数据更新, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f7f212155e0e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007895, encodeId=fa4d200e895bc, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=J Clin Oncol：“照单全治” ——Nivolumab“广谱”治疗复发或难治型经典霍奇金淋巴瘤患者, objectType=article, longId=135028, objectId=c7b113502899, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c7b113502899, replyNumber=0, likeNumber=27, createdTime=2018-08-17, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c7b113502899, moduleTitle=J Clin Oncol：“照单全治” ——Nivolumab“广谱”治疗复发或难治型经典霍奇金淋巴瘤患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c7b113502899)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

NIV

2020-05-29

tamgche (审核中...)

前往app查看评论内容

#NIV#

NEJM：Nivolumab + ipilimumab一线治疗非小细胞肺癌

2019-11-24

tamgche (审核中...)

前往app查看评论内容

#NIV#

2019 ASCO：Nektar Therapeutics公布其IL-2激动剂Bempeg与Nivolumab联用的临床数据

2020-03-12

tamgche (审核中...)

前往app查看评论内容

#NIV#

Lancet Haematology：Nivolumab联合一线化疗治疗急性髓系白血病

2019-09-14

tamgche (审核中...)

前往app查看评论内容

#NIV#

Lancet Oncol：Nivolumab治疗与晚期非小细胞肺癌患者4年生存期

2020-04-22

tamgche (审核中...)

前往app查看评论内容

#NIV#

WCLC 2019：评估脂质体伊立替康（ONIVYDE）作为小细胞肺癌的二线疗法

2020-04-23

tamgche (审核中...)

前往app查看评论内容

#NIV#

晚期非小细胞肺癌一线治疗新方法：TG4010+Nivolumab+化疗方案的II期试验

2020-03-07

tamgche (审核中...)

前往app查看评论内容

#NIV#

Opdivo（nivolumab）联合Yervoy（ipilimumab）具有转移性去势抵抗性前列腺癌患者的治疗希望

2019-08-02

tamgche (审核中...)

前往app查看评论内容

#NIV#

Lancet oncol：Nivolumab联合伊匹单抗或单独用于治疗晚期黑色素瘤可获得持久稳定的疗效

2019-07-17

tamgche (审核中...)

前往app查看评论内容

#NIV#

【2018 ESMO】立足实践，Nivolumab真实世界研究与临床试验结果遥相呼应

2019-02-20

tamgche (审核中...)

前往app查看评论内容

#NIV#

澳大利亚TGA批准OPDIVO（nivolumab）治疗肝癌

2019-09-05

tamgche (审核中...)

前往app查看评论内容

#NIV#

J Endod：Micro-CT观察XP-endo Shaper, Reciproc Blue和ProTaper Universal NiTi对牙本质隐裂形成的

2019-04-02

tamgche (审核中...)

前往app查看评论内容

#NIV#

Lancet：推荐将nivolumab联合伊匹单抗作为无症状未治疗过的黑色素瘤脑转移患者的一线疗法

2018-12-09

tamgche (审核中...)

前往app查看评论内容

#NIV#

JCO：Nivolumab治疗晚期非小细胞肺癌的5 年随访结果

2018-12-02

tamgche (审核中...)

前往app查看评论内容

#NIV#

辉瑞生物仿制药Nivestym获FDA批准用于治疗中性粒细胞减少症

2019-02-27

tamgche (审核中...)

前往app查看评论内容

#NIV#

JCO：Nivolumab和Nivolumab联合Ipilimumab治疗转移性食管胃癌患者

2019-03-05

tamgche (审核中...)

前往app查看评论内容

#NIV#

Lancet Oncol：Nivolumab单抗或是化疗耐药后晚期食管鳞癌的新选择

2018-08-27

tamgche (审核中...)

前往app查看评论内容

#NIV#

治疗黑色素瘤 Opdivo®(Nivolumab)疗效优于Yervoy®(Ipilimumab)

2018-10-11

tamgche (审核中...)

前往app查看评论内容

#NIV#

EUR J Cancer：Pembrolizumab治疗晚期黑色素瘤后使用伊匹单抗/nivolumab治疗的风险较低

2018-01-15

tamgche (审核中...)

前往app查看评论内容

#NIV#

AASLD特约点评 | 赵明教授：Checkmate-040 研究——Nivolumab治疗晚期HCC的数据更新

2018-07-14

tamgche (审核中...)

前往app查看评论内容

#NIV#

J Clin Oncol：“照单全治” ——Nivolumab“广谱”治疗复发或难治型经典霍奇金淋巴瘤患者

2018-08-17

科室
- - 订阅+
  - 更多科室
工具
服务